Biotech

All Articles

A better examine Fierce Biotech's Fierce 15

.Within this full week's episode of "The Top Line," our team're diving into Intense Biotech's annual...

Lilly faces phase 2 breakdown of tau-targeting med

.The confetti is still flying coming from Eli Lilly's gathering celebrating the commendation of Alzh...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of notable leadership hirings, firings and r...

Lykos are going to talk to FDA to reconsider its choice adhering to being rejected of MDMA therapy for post-traumatic stress disorder

.Observing a poor revealing for Lykos Therapies' MDMA prospect for trauma at a recent FDA advising c...

AN 2 fifty percents roll call, ceases phase 3 trial after information disappoint

.AN2 Therapeutics is actually re-thinking its organization in reaction to uninspired midphase inform...

Merck pays $700M for bispecific, spying autoimmune position as well as possibility to challenge Amgen in cancer

.Merck &amp Co. is paying out $700 million ahead of time to challenge Amgen in a blood stream cancer...

Gilead pays out J&ampJ $320M to exit licensing offer for seladelpar

.Along With Gilead Sciences about to an FDA selection for its liver condition drug seladelpar, the f...

' All hands on deck' at Lilly as peers target excessive weight market

.Chief executive officer David Ricks can view the providers putting together outdoors tents at basec...

Entero giving up staff, leaving workplace and pausing R&ampD

.Cushion Liquidators has turned Entero Rehabs white as a sheet. The collector got Entero to settle i...

Exelixis falls ADC after choosing it's no match for Tivdak

.Exelixis is actually surrendering on its cells aspect (TF)- targeting antibody-drug conjugate after...